其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Kainic Acid CAS Registry Number: 487-79-6 海藻酸(mM/ml)

CAS Name: [2S-(2a,3b,4b)]-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid
Additional Names: 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine; digenic acid; a-kainic acid; LS-xylo-kaini...
Literature References: Anthelmintic principle from the dried red alga Digenea simplex (Wulf.) Ag., Rhodomelaceae: Murakami et al., J. Pharm. Soc. Jpn. 73, 1026 (1953); JP 54 4947 (1954), C.A. 49, 13604i (1955); Katsuya et al., JP 64 1942 (1964 to New-Japan Pharmaceutical Co). Structure: Watase, Nitta, Bull. Chem. Soc. Jpn. 30, 889 (1957); Watase et al., ibid. 31, 714 (1958). Eight theoretical stereoisomers, Nitta et al., Nature 181, 761 (1958); GB 795750 (1958 to Takeda). Synthesis: Ueno, US 2902492; Tatsuoka et al., US 2954384 (1959, 1960 both to Takeda); W. Oppolzer, H. Andres, Helv. Chim. Acta 62, 2282 (1979). Excitotoxic amino acid used to identify a specific subset of EAA receptors. Consequently the receptors are known as kainate receptors. Neurotoxic activity: J. V. Nadler, Life Sci. 24, 289 (1979). Mechanism of neurotoxicity: E. G. McGeer et al., Adv. Neurol. 23, 577 (1979); J. T. Coyle et al., ibid. 593; J. W. Ferkany et al., Nature 298, 757 (1982); J. Garthwaite, G. Garthwaite, ibid. 305, 138 (1983). Induces epileptogenic lesions: J. V. Nadler, Neurosci. Res. Program Bull. 19, 369 (1981). Autoradiographic characterization of binding sites: J. T. Greenamyre et al., J. Pharmacol. Exp. Ther. 233, 254 (1985). Book: Kainic Acid as a Tool in Neurobiology, E. G. McGeer et al., Eds. (Raven Press, New York, 1978). Review: J. T. Coyle, Ciba Found. Symp. 126, 186-203 (1987).

Epsiprantel CAS Registry Number: 98123-83-2 依西太尔

CAS Name: 2-(Cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydropyrazino[2,1-a][2]benzazepin-4(1H)-one
Additional Names: 2-cyclohexylcarbonyl-4-oxo-1,2,3,4,6,7,12b-octahydropyrazino[2,1-a][2]benzazepin...
Literature References: Anthelmintic structurally related to praziquantel, q.v. Prepn: R. J. Dorgan, R. L. Elliott, EP 134984; eidem, US 4661489 (1985, 1987 both to Beecham); M. D. Brewer et al., J. Med. Chem. 32, 2058 (1989). Veterinary trials in dogs: R. M. Corwin et al., Am. J. Vet. Res. 50, 1076 (1989); in cats and dogs: B. R. Manger, M. D. Brewer, Br. Vet. J. 145, 384 (1989).

Daunorubicin CAS Registry Number: 20830-81-3 柔红霉素

CAS Name: (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
Additional Names: daunomycin; leukaemom...
Literature References: Anthracycline antibiotic related to the rhodomycins, q.v. Isolated from fermentation broths of Streptomyces peucetius: G. Cassinelli, P. Orezzi, G. Microbiol. 11, 167 (1963), C.A. 62, 9482b (1965); A. Di Marco et al., Nature 201, 706 (1964); eidem, BE 639897; eidem, US 4012284 (1964, 1977 both to Soc. Farmaceut. Italia); S. Pinnert et al., US 3997662 (1976 to Rhone-Poulenc). Daunorubicin is a glycoside formed by a tetracyclic aglycone, daunomycinone, (C21H18O8) and an amino sugar, daunosamine, (C6H13NO3), 3-amino-2,3,6-trideoxy-L-lyxo-hexose: F. Arcamone et al., J. Am. Chem. Soc. 86, 5334, 5335 (1964); R. H. Iwamoto et al., Tetrahedron Lett. 1968, 3891. Absolute stereochemistry: F. Arcamone et al., Gazz. Chim. Ital. 100, 949-989 (1970). Identity with rubidomycin: G. L. Tong et al., J. Pharm. Sci. 56, 1691 (1967). Synthesis of daunosamine: J. P. Marsh et al., Chem. Commun. 1967, 973; T. Yamaguchi, M. Kojimo, Carbohydr. Res. 59, 343 (1977); P. M. Wovkulich, M. R. Uskokovic, J. Am. Chem. Soc. 103, 3956 (1981); of daunomycinone: C. M. Wong et al., Can. J. Chem. 51, 466 (1973); J. S. Swenton, P. W. Reynolds, J. Am. Chem. Soc. 100, 6188 (1978); K. Krohn, K. Tolkiehn, Ber. 112, 3453 (1979); F. M. Hauser, S. Prasanna, J. Am. Chem. Soc. 103, 6378 (1981). Total synthesis of daunorubicin: E. M. Acton et al., J. Med. Chem. 17, 659 (1974). Purification: E. Oppici et al., BE 898506; eidem, GB 2133005 (both 1984 to Farmitalia). Toxicity data: A. Di Marco et al., Cancer Chemother. Rep. Part 1 53, 33 (1969). Review of properties, biosynthesis, fermentation: R. J. White, R. M. Stroshane, Drugs Pharm. Sci. 22, 569-594 (1984); of carcinogenic action in laboratory animals: IARC Monographs 10, 145-152 (1976); of toxicology: R. J. Maral et al., Cancer Treat. Rep. 65, Suppl. 4, 9-18 (1981); of use in treatment of solid tumors: R. B. Weiss et al., ibid. 25-28; of interactions with nucleic acids: S. Neidle, M. R. Sanderson, in Molecular Aspects of Anti-cancer Drug Action, S. Neidle, M. J. Waring, Eds. (Verlag-Chemie, Florida, 1983) pp 35-55; of mechanism of cytotoxicity: H. S. Schwartz, ibid. pp 93-125; of metabolism and clinical pharmacokinetics: C. E. Riggs, Jr., Semin. Oncol. 11, Suppl. 3, 2-11 (1984). Review: A. DiMarco et al., Antibiotics vol. 3, J. W. Corcoran, F. E. Hahn, Eds. (Springer Verlag, New York, 1975) pp 101-128.

Carubicin CAS Registry Number: 50935-04-1 洋红霉素

CAS Name: (8S-cis)-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-5,12-naphthacenedione
Additional Names: (1S,3S)-3-acetyl-1,2,3,4,6,11...
Literature References: Anthracycline antitumor antibiotic, related to daunorubicin and doxorubicin, q.q.v. Isoln from Actinomadura carminata: G. F. Gauze et al., Antibiotiki 18, 675 (1973); M. G. Brazhnikova et al., ibid. 678. Antitumor activity: V. A. Shorin et al., ibid. 681. Physico-chemical characteristics, structure: M. G. Brazhnikova et al., J. Antibiot. 27, 254 (1974). Pharmacokinetics, pharmacodynamics, toxicity study: L. E. Goldberg et al., Antibiotiki 19, 57 (1974). Production: M. G. Brazhnikova et al., SU 508076 (1976 to Inst. Antibiot. Res., USSR), C.A. 86, 15215 (1977). Stereochemistry: eidem, J. Antibiot. 29, 469 (1976). Synthesis from daunomycinone: G. Cassinelli et al., ibid. 31, 178 (1978). Molecular pharmacology: V. H. DuVernay et al., Cancer Res. 40, 387 (1980). Analysis in human serum: S. E. Fandrich, K. A. Pittman, J. Chromatogr. 223, 155 (1981). Early clinical studies: L.H. Baker et al., Cancer Treat. Rep. 63, 899 (1979). Embryotoxicity and teratogenicity study: I. Damjanov, A. Celluzzi, Res. Commun. Chem. Pathol. Pharmacol. 28, 497 (1980).

Glucofrangulin CAS Registry Number: 52731-38-1 1,6-二羟基-3-甲基-8-(((2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)蒽-9,10-二酮

Trademarks: Erbalax-N (Erba); Irgalax (Novartis)
Percent Composition: C 56.05%, H 5.23%, O 38.72%
Literature References: Anthraquinone glycoside from bark of Rhamnus frangula L., Rhamnaceae (alder buckthorn): Casparis, Maeder, Bull. Soc. Chim. Biol. 9, 324 (1927); Cucu, Jarpo, Pharmazie 14, 316 (1959); Knap et al., CS 110024 (1964), C.A. 61, 4159e (1964). Consists of two isomers, glucofrangulin A and glucofrangulin B, which differ by the linkage to the sugar moiety at the 3 position of the aglycone. Structure: Schindler, Helv. Chim. Acta 29, 411 (1946); Hörhammer et al., Naturwissenschaften 51, 310 (1964); Longo et al., Arch. Pharm. 297, 248 (1964); Wagner, Hörhammer, Naturwissenschaften 53, 585 (1966). Proof of structure of glucofrangulin A and partial synthesis: eidem, Z. Naturforsch. 24B, 1408 (1969).

Traxanox CAS Registry Number: 58712-69-9 四唑吡色酮

CAS Name: 9-Chloro-7-(1H-tetrazol-5-yl)-5H-[1]benzopyrano[2,3-b]pyridin-5-one
Additional Names: 9-chloro-7-(5-1H-tetrazolyl)-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine
Percent Composition: C 52....
Literature References: Antiallergic agent which selectively inhibits release of allergic mediators from mast cells. Prepn: T. Oe, M. Tsuruda, DE 2521980; eidem, US 4085111 (1975, 1978 both to Yoshitomi). Antianaphylactic activity in animals: K. Goto et al., Jpn. J. Pharmacol. 30, 537 (1980). Mechanism of action study: K. Goto et al., Int. Arch. Allergy Appl. Immunol. 68, 332 (1982). Clinical pharmacology and pharmacokinetics: A. Ebihara et al., Arzneim.-Forsch. 37, 1388 (1987). Metabolism in humans: M. Tateno et al., Yakuri to Chiryo 16, 3251 (1988), C.A. 110, 18040n (1989).

Glaucarubin CAS Registry Number: 1448-23-3 格劳卡昔

CAS Name: [1b,2a,11b,12a,15b(S)]-11,20-Epoxy-1,2,11,12-tetrahydroxy-15-(2-hydroxy-2-methyl-1-oxobutoxy)picras-3-en-16-one
Additional Names: 2-hydroxy-2-methylbutyric acid 4-ester with 1,2,3,3ab...
Literature References: Antiamebic compound isolated from seeds of Simaruba glauca DC, Simarubaceae: E. A. Ham et al., J. Am. Chem. Soc. 76, 6066 (1954); H. M. Shafer, US 2864745 (1958 to Merck Co.). Pharmacology: A. C. Cuckler et al., Arch. Int. Pharmacodyn. 114, 307 (1958). Structure: Polonsky et al., Bull. Soc. Chim. Fr. 1964, 1827. Identity of a- and b-kirondrin with glaucarubinone and glaucarubin, resp: Bourguignon, Polonsky, Bull. Soc. Chim. Biol. 46, 1145 (1964). Crystal structure: Kartha et al., Nature 202, 389 (1964). Configuration: Nyburg et al., Chem. Commun. 1965, 203.

Chonemorphine CAS Registry Number: 4282-07-9 鹿角藤碱

CAS Name: (3b,5a,20S)-N20,N20-Dimethylpregnane-3,20-diamine
Additional Names: 3b-amino-20a-dimethylamino-5a-pregnane
Percent Composition: C 79.70%, H 12.21%, N 8.08%
Literature References: Antiamebic principle from bark and leaves of Chonemorpha macrophylla G. Don, Ch. fragrans Alston, and Ch. penangensis Ridl., Apocynaceae: Greshoff, Ber. 23, 3545 (1890); Das, Pillay, J. Sci. Ind. Res. 13B, 602, 701 (1954); Chatterjee, Das, Chem. Ind. (London) 1959, 1445. Structure and synthesis: eidem, ibid. 1960, 290; Janot et al., Bull. Soc. Chim. Fr. 1962, 111. Stereochemistry: Chien et al., J. Org. Chem. 29, 315 (1964).

Tocainide CAS Registry Number: 41708-72-9 2-氨基-N-(2,6-二甲基苯基)丙酰胺

CAS Name: 2-Amino-N-(2,6-dimethylphenyl)propanamide
Additional Names: 2-aminopropiono-2',6'-xylidide
Percent Composition: C 68.72%, H 8.39%, N 14.57%, O 8.32%
Literature References: Anti-arrhythmic agent related to lidocaine, q.v. Prepn: R. N. Boys et al., DE 2235745 (1973 to Astra), C.A. 78, 140411 (1973); and resolution of isomers: E. W. Byrnes et al., J. Med. Chem. 22, 1171 (1979). In vitro effects on muscle contractions: R. Dengler, R. Rüdel, Arzneim.-Forsch. 29, 270 (1979). Inhibition of leucocyte locomotion in dogs: G. J. Stewart et al., Lab. Invest. 42, 302 (1980). Biotransformation in humans: A. T. Elvin et al., J. Pharm. Sci. 69, 47 (1980). Kinetics: C. Groffner, Clin. Pharmacol. Ther. 27, 64 (1980). Use in refractory ventricular arrhythmias: D. M. Roden et al., Am. Heart J. 100, 15 (1980). HPLC resolution of enantiomers: K. M. McErlane, G. K. Pillai, J. Chromatogr. 274, 129 (1983); determn in plasma: A. J. Sedman, J. Gal, ibid. 306, 155 (1984). Pharmacokinetics of enantiomers: A. H. Thomson et al., Br. J. Pharmacol. 21, 149 (1986). In vitro and in vivo pharmacodynamics of enantiomers: A. J. Block et al., J. Cardiovasc. Pharmacol. 11, 216 (1988). Review of pharmacology and therapeutic efficacy: B. Holmes et al., Drugs 26, 93-123 (1983); D. M. Roden, R. L. Woosley, N. Engl. J. Med. 315, 41-45 (1986).

Butobendine CAS Registry Number: 55769-65-8 布托苯定

CAS Name: 3,4,5-Trimethoxybenzoic acid 1,2-ethanediylbis[(methylimino)[(2S)-2-ethyl-2,1-ethanediyl]] ester
Additional Names: (2S,2'S)-N,N'-dimethyl-N,N'-bis-1-(3',4',5'-trimethoxybenzoyloxy)but...
Literature References: Antiarrhythmic agent which increases cardiac blood flow. Prepn: M. Eckstein et al., DE 2435380; eidem, US 4021473 (1975, 1977 both to Polfa). Series of articles on pharmacology, pharmacokinetics, toxicology: Pol. J. Pharmacol. Pharm. 32, 817-953 (1980). Physical properties: L. Krowczynski et al., ibid. 909. Toxicity data: J. Maj et al., ibid. 823.